Landscapes / Companies
Johnson & Johnson (Janssen)
Public JNJ · United States
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
18 approved
13 in Phase 3
Drugs
59
in active trials · 276 in all
Trials
172 active
747 since 2021
Drugs59
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Approved | 1 Dec 2026soonPhase 3 trial completes | |||
| Next date | 1 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer and 7 more | ||||
| Open drug page | |||||
Nipocalimabnot checked |
Monoclonal antibody |
Approved | 15 Dec 2026soonPhase 2/3 trial completes | ||
| How it works | An antibody | ||||
| Next date | 15 Dec 2026 · Phase 2/3 trial completes | ||||
| Also tested for | Myasthenia Gravis, Thrombocytopenia, Neonatal Alloimmune and 5 more | ||||
| Open drug page | |||||
Cytochrome P450 17A1 inhibitor |
Approved | 31 Dec 2026Phase 1 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer and 5 more | ||||
| Open drug page | |||||
Amivantamabnot checked |
Monoclonal antibody |
Approved | 31 Jan 2027Phase 1/2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 31 Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck and 6 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 10 Feb 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 10 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Colitis, Ulcerative, Arthritis, Psoriatic and 8 more | ||||
| Open drug page | |||||
— |
Approved | 10 Feb 2027Phase 3 trial completes | |||
| Next date | 10 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Plaque Psoriasis, Arthritis, Psoriatic and 4 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 12 Feb 2027Phase 4 trial completes | |||
| How it works | An antibody | ||||
| Next date | 12 Feb 2027 · Phase 4 trial completes | ||||
| Also tested for | Multiple Myeloma, Hematological Malignancies and 1 more | ||||
| Open drug page | |||||
— |
Approved | 26 Feb 2027Phase 2 trial completes | |||
| Next date | 26 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Multiple Myeloma | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 26 Feb 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 26 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Multiple Myeloma, Amyloidosis and 2 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 31 May 2027Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 May 2027 · Phase 2 trial completes | ||||
| Also tested for | Carcinoma, Non-Small-Cell Lung, Non-Small-Cell Lung Cancer and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 30 Jun 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 30 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Multiple Myeloma, Hematological Malignancies and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 29 Sep 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 29 Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Crohn's Disease, Crohn Disease and 3 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 30 Mar 2028Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Mar 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Urothelial Cancer, Urothelial Carcinoma and 1 more | ||||
| Open drug page | |||||
— |
Approved in the EU | 30 Jun 2028Phase 3 trial completes | |||
| Next date | 30 Jun 2028 · Phase 3 trial completes | ||||
| Also tested for | Carcinoma, Squamous Cell, Carcinoma, Non-Small-Cell Lung and 1 more | ||||
| Open drug page | |||||
— |
Approved | 27 Dec 2028Phase 3 trial completes | |||
| Next date | 27 Dec 2028 · Phase 3 trial completes | ||||
| Also tested for | Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | — | |||
| How it works | An antibody | ||||
| Also tested for | Colitis, Ulcerative, Crohn's Disease | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | — | |||
| How it works | An antibody | ||||
| Also tested for | Colitis, Ulcerative | ||||
| Open drug page | |||||
— |
Approved | — | |||
| Also tested for | Prostatic Neoplasms | ||||
| Open drug page | |||||
Factor XIa inhibitor |
Bristol Myers Squibb |
Phase 3 | 8 Dec 2026soonPhase 3 trial completes | ||
| Next date | 8 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Ischemic Stroke; Ischemic Attack, Transient, Atrial Fibrillation | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | 30 Dec 2026Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 30 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Neoplasms, Urinary Bladder Neoplasms and 6 more | ||||
| Open drug page | |||||
No drugs match “”.
SEC filings
All on SEC.govNo filings loaded yet.
About
- No active trial
- 217 other drugs
- Registry names
- 21 names in ClinicalTrials.gov Janssen Research & Development, LLC
Janssen Vaccines & Prevention B.V.
Janssen Pharmaceutical K.K.
Janssen-Cilag International NV
Janssen Sciences Ireland UC
Janssen Pharmaceutica N.V., Belgium
Janssen Scientific Affairs, LLC
Johnson & Johnson Consumer Inc. (J&JCI)
Janssen-Cilag Ltd.
Johnson & Johnson Private Limited
Johnson & Johnson Enterprise Innovation Inc.
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Johnson & Johnson Vision Care, Inc.
Xian-Janssen Pharmaceutical Ltd.
Janssen Korea, Ltd., Korea
Johnson & Johnson Taiwan Ltd
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Janssen R&D Ireland
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Janssen-Cilag, S.A.
Janssen Biotech, Inc. - Sources
- ClinicalTrials.gov updated 18 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021